Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Well-Funded Seres Races To Be First To Market With A Microbiome Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

After raising $143 million from an IPO in June, Seres Therapeutics is hoping its lead development candidate SER-109, in Phase II for Clostridium difficile, could be the first microbiome-based drug to reach the market.

You may also be interested in...



Seres Argues Different Diagnostic Needed In Recurrent C. Difficile Trials

As it talks study design with FDA, Seres says new analysis of Phase II trial of microbiome candidate SER-109 suggests that a C. difficile cytotoxin test would be more accurate and that a higher dose may be more effective.

Radius Business Review Ends In Sale To Investment Funds

Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS078862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel